As of Friday close, FibroGen Inc.’s (NASDAQ:FGEN) stock was down -$0.05, moving down -6.50 percent to $0.79. The average number of shares traded per day over the past five days has been 8,162,480 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0731 fall in that time frame. In the last twenty days, the average volume was 6,522,550, while in the previous 50 days, it was 4,503,254.
Since last month, FGEN stock retreated -37.10%. Shares of the company fell to $0.7010 on 09/19/23, the lowest level in the past month. A 52-week high of $25.69 was reached on 02/03/23 after having rallying from a 52-week low of $0.70. Since the beginning of this year, FGEN’s stock price has dropped by -95.09% or -$15.2300, and marked a new high 10 times. However, the stock has declined by -96.94% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
FGEN stock investors should be aware that FibroGen Inc. (FGEN) stock had its last reported insider trading activity 22 days ago on Sep 01. Henderson Jeffrey William, the Director of the company, disposed of 2,000 shares for $1.03 on Sep 01. It resulted in a $2,060 divestment by the insider. Henderson Jeffrey William sold 2,000 shares at an average price of $1.91 on Aug 04. The insider now owns 30,866 shares following the transaction. On Jul 11, Director Henderson Jeffrey William sold 2,000 shares at $2.69 apiece. The transaction was valued at $5,380.
Financial Health
In the three months ended June 29, FibroGen Inc.’s quick ratio stood at 1.90, while its current ratio was 2.10, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 85.90% percent. Based on annual data, FGEN earned $120.45 million in gross profit and brought in $140.73 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 7008.90%. Return on equity (ROE) for the past 12 months was 881.20%.
In FibroGen Inc.’s quarter-end financial report for June 29, it reported total debt of $71.41 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. FGEN’s revenue rose 32.74% to $36.16 million during the quarter, while net income inched up to $44.32 million. While analysts expected FibroGen Inc. to report -$0.7 quarterly earnings, the actual figure was -$0.9 per share, beating the consensus estimate by -28.60%. During the quarter, the company generated -$86.46 million in EBITDA. The liabilities of FibroGen Inc. were 596.91 million at the end of its most recent quarter ended June 29, and its total debt was $173.6 million. The value of shareholders’ equity is $98.21 million.
Technical Picture
This quick technical analysis looks at FibroGen Inc.’s (FGEN) price momentum. With a historical volatility rate of 86.56%, the RSI 9-day stood at 31.14% on 22 September.
With respect to its five-day moving average, the current FibroGen Inc. price is down by -8.47% percent or -$0.0731. At present, FGEN shares trade -35.77% below its 20-day simple moving average and -95.21% percent below its 100-day simple moving average. However, the stock is currently trading approximately -70.41% below its SMA50 and -95.12% below its SMA200.
Stochastic coefficient K was 32.81% and Stochastic coefficient D was 29.30%, while ATR was 0.1135. Given the Stochastic reading of 21.76% for the 14-day period, the RSI (14) reading has been calculated as 27.43%. As of today, the MACD Oscillator reading stands at -0.0287, while the 14-day reading stands at -0.0825.
Analyst Ratings
FibroGen Inc. downgraded its rating on FibroGen Inc. (NASDAQ: FGEN) to an Underperform in a note to investors on August 08, 2023. The analysts firm previously had a Neutral rating on the stock.FibroGen Inc. (FGEN) has been rated Underweight by analysts. According to 1 brokerage firm, FGEN is a sell, and 3 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate FibroGen Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $2.25, the current consensus forecast for the stock is $2.00 – $2.50. Based on these forecasts, analysts predict FibroGen Inc. (FGEN) will achieve an average price target of $2.25.
